S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Celgene Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Corporation|
|Celgene to Present Long-Term Efficacy and Safety Data on Oral OTEZLA® (apremilast) in Plaque Psoriasis and Psoriatic Arthritis at European Academy of Dermatology and Venereology Congress|
|Phase II Data in Crohn’s Disease for Celgene’s Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014|
|Celgene Receives Positive CHMP Opinion for OTEZLA® (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis|
|Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress|
|New Analyses of Oral OTEZLA® (Apremilast) Presented at EADV Show Efficacy in Difficult-to-Treat Areas of Moderate to Severe Plaque Psoriasis|
|Oral OTEZLA® (apremilast) Data Presented at EADV Show Improved Measures of Health-Related Quality of Life and Work Productivity in Patients with Moderate to Severe Plaque Psoriasis|
|Zeldes Haeggquist & Eck, LLP Announces Investigation of Celgene, Inc. (2014/9/22)|
|Data from More Than 160 Abstracts Highlighting Celgene Therapies to Be Presented at American Society of Hematology Annual Meeting (ASH)|
|Celgene Reports Third Quarter 2014 Operating and Financial Results|
Click above to view more mutual fund data and stats for celg - Celgene Corp.